Frailty, Aging, and Risk of Adverse Outcomes in Mitral Valve Prolapse (FAR-OUT-MVP Study)
二尖瓣脱垂的虚弱、衰老和不良后果风险(FAR-OUT-MVP 研究)
基本信息
- 批准号:10836297
- 负责人:
- 金额:$ 17.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:Accident and Emergency departmentAdverse eventAgeAgingArrhythmiaAtrial FibrillationAttenuatedBenignBlood flowCardiacCardiovascular systemCase MixesCommunitiesDataData LinkagesData SetData SourcesDatabasesDecision MakingDevelopmentDiseaseEchocardiographyEmployeeEndocarditisEnrollmentEventFibrosisFutureGeneral PopulationHeart Valve DiseasesHeart failureHeterogeneityHomeostasisImageImpairmentImplantable DefibrillatorsIndividualInpatientsInstitutionInsuranceInvestigationIsraelLeftLinkMagnetic ResonanceMassachusettsMedical centerMitral ValveMitral Valve InsufficiencyMitral Valve ProlapseMorbidity - disease rateMyocardialMyocardial ContractionNational Heart, Lung, and Blood InstituteNatural HistoryOutcomeOutpatientsPatientsPhenotypePhysiologicalPopulationPrevalencePrivatizationPrognosisProviderRegistriesReportingRiskRisk FactorsRoleRuptureSecondary toSeveritiesStressful EventStretchingStructureSurvivorsSystemTissuesVentricularVentricular ArrhythmiaVulnerable Populationsadverse event riskadverse outcomeaortic valve disordercardiac magnetic resonance imagingcardiovascular risk factorcerebrovascularclinically relevantcohortfrailtyheart imaginghigh riskhuman old age (65+)imaging biomarkerimprovedinsightmitral valve replacementmortalitymortality risknovelpapillary musclerepairedstressorstructured datasudden cardiac death
项目摘要
PROJECT SUMMARY
Mitral valve prolapse (MVP) is a common cardiac valvular disease, with a prevalence of roughly 2-3% in the
general population, associated with excess mitral valve or chordal tissue may predispose to the development
of mitral regurgitation (MR) from leaflet malcoaptation and chordal rupture. This condition and its sequelae,
detected on echocardiograms (TTEs) and cardiac magnetic resonance images (CMRs), has been previously
felt to be associated with an overall benign prognosis. Recent evidence suggest a subset of individuals with
MVP have an excess risk of cardiovascular and non-cardiovascular morbidity and mortality, including
ventricular arrhythmias and sudden cardiac death. Despite known risks of MVP, it remains challenging to
identify high risk subsets in need of further treatments such as implantable defibrillator use or mitral
valve repair or replacement. Furthermore, disaggregating the risk of MVP from that of concomitant MR
remains challenging at present. Moreover, while individual imaging biomarkers of risk have been identified,
which of these independently influence MVP risk when considered together remains unclear. While relevant
clinical risk factors including aging and frailty, “a state of increased vulnerability and reduced ability to maintain
homeostasis after a stressful event resulting from an impairment in multiple physiologic systems,” have found
to influence outcome risk in other valvular heart diseases, it remains unclear if aging and frailty modify the risk
of MVP on adverse outcomes. This proposal leverages the unique linkage of two large data sources,
structured datasets of TTE and CMR reports from Beth Israel Deaconess Medical Center, and all-payer
statewide claims data from the Massachusetts Case Mix Dataset (MACM) to better evaluate the risk of MVP
across the spectrum of age and frailty. In this study, we propose to directly link BIDMC TTE and CMR reports
to MACM data to evaluate whether MVP is associated with a risk of mortality, cardiovascular morbidity
(composite of heart failure, atrial fibrillation, cerebrovascular event, endocarditis), and need for mitral valve
replacement or repair, and whether this risk relationship varies by age and frailty as well as operative status
(receipt of mitral valve replacement or repair). Doing so, this study will provide greater insight into the
role that aging and frailty may have on the risk of serious outcomes associated with MVP and build a
unique registry of cardiac imaging information linked to outcome data that could be leveraged in the
future to deepen understanding of MVP as well as other valvular heart diseases.
项目摘要
二尖瓣脱垂(MVP)是一种常见的心脏瓣膜疾病,在美国的患病率约为2-3%。
一般人群,与二尖瓣或腱索组织过多相关,可能易发生
瓣叶对合不良和腱索断裂导致的二尖瓣返流(MR)。这种情况及其后遗症,
在超声心动图(TTE)和心脏磁共振图像(CMR)上检测到,
被认为与总体良性预后相关。最近的证据表明,一个子集的个人与
MVP具有心血管和非心血管发病率和死亡率的过度风险,包括
室性心律失常和心源性猝死。尽管已知MVP的风险,
识别需要进一步治疗的高风险子集,例如使用植入式除颤器或二尖瓣
瓣膜修复或置换。此外,将MVP的风险与伴随MR的风险分开
目前仍然具有挑战性。此外,虽然已经确定了风险的个体成像生物标志物,
当一起考虑时,这些因素中的哪一个独立地影响MVP风险仍然不清楚。而相关
临床风险因素包括衰老和虚弱,“脆弱性增加和维持能力降低的状态
在多种生理系统受损导致的应激事件后的体内平衡,”已经发现
影响其他心脏瓣膜疾病的预后风险,但年龄和虚弱是否会改变风险仍不清楚
关于不良后果的MVP。该提案利用了两个大型数据源的独特链接,
来自Beth Israel Deaconess Medical Center和所有付款人的TTE和CMR报告的结构化数据集
来自马萨诸塞州病例组合数据集(MACM)的全州索赔数据,以更好地评估MVP的风险
跨越年龄和脆弱的范围。在这项研究中,我们建议直接链接BIDMC TTE和CMR报告
MACM数据,以评估MVP是否与死亡率、心血管发病率
(心力衰竭、房颤、脑血管事件、心内膜炎的复合终点),需要二尖瓣
置换或修复,以及这种风险关系是否因年龄和虚弱以及手术状态而异
(接受二尖瓣置换或修复)。这样做,这项研究将提供更深入的了解
衰老和虚弱可能对MVP相关严重结局风险的作用,并建立一个
与结局数据相关的心脏成像信息的唯一注册表,
以期加深对MVP及其他心脏瓣膜病的认识。
项目成果
期刊论文数量(25)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Moderate aortic stenosis: culprit or bystander?
- DOI:10.1136/openhrt-2021-001743
- 发表时间:2022-01
- 期刊:
- 影响因子:2.7
- 作者:Pankayatselvan V;Raber I;Playford D;Stewart S;Strange G;Strom JB
- 通讯作者:Strom JB
Echocardiographic Progression of Peak Tricuspid Regurgitant Velocity Among Medicare Beneficiaries.
医疗保险受益人三尖瓣反流峰值速度的超声心动图进展。
- DOI:10.1016/j.jacadv.2023.100579
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Kholdani,CyrusA;Choudhary,Gaurav;Furfaro,DavidM;Markson,LawrenceJ;Manning,WarrenJ;Strom,JordanB
- 通讯作者:Strom,JordanB
The Association of Weekly Sonographer Feedback and Reduction in Sonographer Errors.
- DOI:10.1016/j.echo.2021.08.011
- 发表时间:2021-11
- 期刊:
- 影响因子:0
- 作者:Fostello SE;Stout JL;Manning WJ;Strom JB
- 通讯作者:Strom JB
Retrospective evaluation of echocardiographic variables for prediction of heart failure hospitalization in heart failure with preserved versus reduced ejection fraction: A single center experience.
- DOI:10.1371/journal.pone.0244379
- 发表时间:2020
- 期刊:
- 影响因子:3.7
- 作者:Hammond MM;Shen C;Li S;Kazi DS;Sabe MA;Garan AR;Markson LJ;Manning WJ;Klein AL;Nagueh SF;Strom JB
- 通讯作者:Strom JB
Race, sex and age disparities in echocardiography among Medicare beneficiaries in an integrated healthcare system.
综合医疗保健系统中医疗保险受益人超声心动图的种族,性别和年龄差异。
- DOI:10.1136/heartjnl-2021-319951
- 发表时间:2022-05-25
- 期刊:
- 影响因子:5.7
- 作者:Hyland, Patrick M.;Xu, Jiaman;Shen, Changyu;Markson, Lawrence J.;Manning, Warren J.;Strom, Jordan B.
- 通讯作者:Strom, Jordan B.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jordan Blair Strom其他文献
Jordan Blair Strom的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jordan Blair Strom', 18)}}的其他基金
Chronic Renal Insufficiency and Silent Progression of Aortic Stenosis (CRISP-AS)
慢性肾功能不全和无症状进展的主动脉瓣狭窄 (CRISP-AS)
- 批准号:
10718275 - 财政年份:2023
- 资助金额:
$ 17.28万 - 项目类别:
Identification of the Components of Frailty Using Administrative Data and Metabolite Profiling
使用管理数据和代谢物分析识别虚弱的组成部分
- 批准号:
10441266 - 财政年份:2019
- 资助金额:
$ 17.28万 - 项目类别:
Identification of the Components of Frailty Using Administrative Data and Metabolite Profiling
使用管理数据和代谢物分析识别虚弱的组成部分
- 批准号:
10217235 - 财政年份:2019
- 资助金额:
$ 17.28万 - 项目类别:
Identification of the Components of Frailty Using Administrative Data and Metabolite Profiling
使用管理数据和代谢物分析识别虚弱的组成部分
- 批准号:
10657394 - 财政年份:2019
- 资助金额:
$ 17.28万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 17.28万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 17.28万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 17.28万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 17.28万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 17.28万 - 项目类别:














{{item.name}}会员




